On August 10, AKESO rose 4% in regular trading, trading at 102.6 HKD/share, with turnover of 98.30 million HKD.

On the news front, the company is seeing intensive clinical pipeline progress. Overseas partner Summit has initiated an international Phase II/III registrational study of ivonescimab combined with enfortumab vedotin head-to-head against pembrolizumab plus enfortumab vedotin in first-line urothelial carcinoma. This marks the 16th registrational/Phase III clinical trial and the 6th international multi-center registrational study for ivonescimab, representing a key deployment of the company's IO2.0+ADC2.0 strategy in urologic oncology.

Simultaneously, cadonilimab (PD-1/CTLA-4 bispecific antibody) has launched a Phase III head-to-head study against nivolumab in first-line gastric cancer, with a planned enrollment of 950 patients. These developments underscore the accelerating global commercialization of the company's bispecific antibody portfolio across multiple tumor types.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)